Overexpressing S100A9 ameliorates NK cell dysfunction in estrogen receptor-positive breast cancer.
Breast cancer
NK cell
S100A9
Tumor microenvironment
Journal
Cancer immunology, immunotherapy : CII
ISSN: 1432-0851
Titre abrégé: Cancer Immunol Immunother
Pays: Germany
ID NLM: 8605732
Informations de publication
Date de publication:
07 May 2024
07 May 2024
Historique:
received:
08
02
2024
accepted:
01
04
2024
medline:
7
5
2024
pubmed:
7
5
2024
entrez:
7
5
2024
Statut:
epublish
Résumé
Estrogen receptor (ER) positive human epidermal growth factor receptor 2 (HER2) negative breast cancer (ER+/HER2-BC) and triple-negative breast cancer (TNBC) are two distinct breast cancer molecular subtypes, especially in tumor immune microenvironment (TIME). The TIME of TNBC is considered to be more inflammatory than that of ER+/HER2-BC. Natural killer (NK) cells are innate lymphocytes that play an important role of tumor eradication in TME. However, studies focusing on the different cell states of NK cells in breast cancer subtypes are still inadequate. In this study, single-cell mRNA sequencing (scRNA-seq) and bulk mRNA sequencing data from ER+/HER2-BC and TNBC were analyzed. Key regulator of NK cell suppression in ER+/HER2-BC, S100A9, was quantified by qPCR and ELISA in MCF-7, T47D, MDA-MB-468 and MDA-MB-231 cell lines. The prognosis predictability of S100A9 and NK activation markers was evaluated by Kaplan-Meier analyses using TCGA-BRAC data. The phenotype changes of NK cells in ER+/HER2-BC after overexpressing S100A9 in cancer cells were evaluated by the production levels of IFN-gamma, perforin and granzyme B and cytotoxicity assay. By analyzing scRNA-seq data, we found that multiple genes involved in cellular stress response were upregulated in ER+/HER2-BC compared with TNBC. Moreover, TLR regulation pathway was significantly enriched using differentially expressed genes (DEGs) from comparing the transcriptome data of ER+/HER2-BC and TNBC cancer cells, and NK cell infiltration high/low groups. Among the DEGs, S100A9 was identified as a key regulator. Patients with higher expression levels of S100A9 and NK cell activation markers had better overall survival. Furthermore, we proved that overexpression of S100A9 in ER+/HER2-cells could improve cocultured NK cell function. In conclusion, the study we presented demonstrated that NK cells in ER+/HER2-BC were hypofunctional, and S100A9 was an important regulator of NK cell function in ER+BC. Our work contributes to elucidate the regulatory networks between cancer cells and NK cells and may provide theoretical basis for novel drug development.
Sections du résumé
BACKGROUND
BACKGROUND
Estrogen receptor (ER) positive human epidermal growth factor receptor 2 (HER2) negative breast cancer (ER+/HER2-BC) and triple-negative breast cancer (TNBC) are two distinct breast cancer molecular subtypes, especially in tumor immune microenvironment (TIME). The TIME of TNBC is considered to be more inflammatory than that of ER+/HER2-BC. Natural killer (NK) cells are innate lymphocytes that play an important role of tumor eradication in TME. However, studies focusing on the different cell states of NK cells in breast cancer subtypes are still inadequate.
METHODS
METHODS
In this study, single-cell mRNA sequencing (scRNA-seq) and bulk mRNA sequencing data from ER+/HER2-BC and TNBC were analyzed. Key regulator of NK cell suppression in ER+/HER2-BC, S100A9, was quantified by qPCR and ELISA in MCF-7, T47D, MDA-MB-468 and MDA-MB-231 cell lines. The prognosis predictability of S100A9 and NK activation markers was evaluated by Kaplan-Meier analyses using TCGA-BRAC data. The phenotype changes of NK cells in ER+/HER2-BC after overexpressing S100A9 in cancer cells were evaluated by the production levels of IFN-gamma, perforin and granzyme B and cytotoxicity assay.
RESULTS
RESULTS
By analyzing scRNA-seq data, we found that multiple genes involved in cellular stress response were upregulated in ER+/HER2-BC compared with TNBC. Moreover, TLR regulation pathway was significantly enriched using differentially expressed genes (DEGs) from comparing the transcriptome data of ER+/HER2-BC and TNBC cancer cells, and NK cell infiltration high/low groups. Among the DEGs, S100A9 was identified as a key regulator. Patients with higher expression levels of S100A9 and NK cell activation markers had better overall survival. Furthermore, we proved that overexpression of S100A9 in ER+/HER2-cells could improve cocultured NK cell function.
CONCLUSION
CONCLUSIONS
In conclusion, the study we presented demonstrated that NK cells in ER+/HER2-BC were hypofunctional, and S100A9 was an important regulator of NK cell function in ER+BC. Our work contributes to elucidate the regulatory networks between cancer cells and NK cells and may provide theoretical basis for novel drug development.
Identifiants
pubmed: 38713229
doi: 10.1007/s00262-024-03699-1
pii: 10.1007/s00262-024-03699-1
doi:
Substances chimiques
Calgranulin B
0
Receptors, Estrogen
0
S100A9 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
117Subventions
Organisme : National Natural Science Foundation of China
ID : 82002791
Informations de copyright
© 2024. The Author(s).
Références
Binnewies M, Roberts EW, Kersten K, Chan VA-O, Fearon DF, Merad M, Coussens LM, Gabrilovich DI, Ostrand-Rosenberg SA-O, Hedrick CC, Vonderheide RH, Pittet MJ, Jain RK, Zou W, Howcroft TK, Woodhouse EC, Weinberg RA, Krummel MA-O, Understanding the tumor immune microenvironment (TIME) for effective therapy. (1546–170X (Electronic))
Ruffell B, DeNardo DG, Affara NI, Coussens LM (2010) Lymphocytes in cancer development: polarization towards pro-tumor immunity. Cytokine Growth Factor Rev 21(1):3–10
pubmed: 20005150
doi: 10.1016/j.cytogfr.2009.11.002
Dhatchinamoorthy K, Colbert JD, Rock KL (2021) Cancer immune evasion through loss of MHC class I antigen presentation. Front Immunol 12:636568
pubmed: 33767702
pmcid: 7986854
doi: 10.3389/fimmu.2021.636568
Nicolai CJ, Wolf N, Chang IC, Kirn G, Marcus A, Ndubaku CO, McWhirter SM, Raulet DH (2020) NK cells mediate clearance of CD8+ T cell-resistant tumors in response to STING agonists. Sci Immunol 5(45):eaaz2738
pubmed: 32198222
pmcid: 7228660
doi: 10.1126/sciimmunol.aaz2738
Zhu Y, Zhu X, Tang C, Guan X, Zhang W (2021) Progress and challenges of immunotherapy in triple-negative breast cancer. Biochimica Et Biophysica Acta Rev Cancer 1876(2):188593
doi: 10.1016/j.bbcan.2021.188593
Onkar SS, Carleton NM, Lucas PC, Bruno TC, Lee AV, Vignali DAA, Oesterreich S (2023) The great immune escape: understanding the divergent immune response in breast cancer subtypes. Cancer Discov 13(1):23–40
pubmed: 36620880
pmcid: 9833841
doi: 10.1158/2159-8290.CD-22-0475
Portale F, Di Mitri D (2023) NK cells in cancer: mechanisms of dysfunction and therapeutic potential. Int J Mol Sci 24(11):9521
pubmed: 37298470
pmcid: 10253405
doi: 10.3390/ijms24119521
Wang T, Jin J, Qian C, Lou J, Lin J, Xu A, Xia K, Jin L, Liu B, Tao H, Yang Z, Yu W (2021) Estrogen/ER in anti-tumor immunity regulation to tumor cell and tumor microenvironment. Cancer Cell Int 21(1):295
pubmed: 34098945
pmcid: 8182917
doi: 10.1186/s12935-021-02003-w
Shi Y, Pan J, Hang C, Tan L, Hu L, Yan Z, Zhu J (2023) The estrogen/miR-338-3p/ADAM17 axis enhances the viability of breast cancer cells via suppressing NK cell’s function. Environ Toxicol 38(7):1618–1627
pubmed: 37052432
doi: 10.1002/tox.23791
Bresnick AR, Weber DJ, Zimmer DB (2015) S100 proteins in cancer. Nat Rev Cancer 15(2):96–109
pubmed: 25614008
pmcid: 4369764
doi: 10.1038/nrc3893
Chen Y, Ouyang Y, Li Z, Wang X, Ma J (2023) S100A8 and S100A9 in Cancer. Biochimica Et Biophysica Acta Rev Cancer 1878(3):188891
doi: 10.1016/j.bbcan.2023.188891
Kwak T, Wang F, Deng H, Condamine T, Kumar V, Perego M, Kossenkov A, Montaner LJ, Xu X, Xu W, Zheng C, Schuchter LM, Amaravadi RK, Mitchell TC, Karakousis GC, Mulligan C, Nam B, Masters G, Hockstein N, Bennett J, Nefedova Y, Gabrilovich DI (2020) Distinct populations of immune-suppressive macrophages differentiate from monocytic myeloid-derived suppressor cells in cancer. Cell Rep 33(13):108571
pubmed: 33378668
pmcid: 7809772
doi: 10.1016/j.celrep.2020.108571
Narumi K, Miyakawa R, Ueda R, Hashimoto H, Yamamoto Y, Yoshida T, Aoki K (2015) Proinflammatory proteins S100A8/S100A9 activate NK Cells via interaction with RAGE. J Immunol 194(11):5539–5548
pubmed: 25911757
doi: 10.4049/jimmunol.1402301
Weinstein JN, Collisson EA, Mills GB, Shaw KRM, Ozenberger BA, Ellrott K, Shmulevich I, Sander C, Stuart JM (2013) The cancer genome atlas pan-cancer analysis project. Nat Genet 45(10):1113–1120
pubmed: 24071849
pmcid: 3919969
doi: 10.1038/ng.2764
Wu SZ, Al-Eryani G, Roden DL, Junankar S, Harvey K, Andersson A, Thennavan A, Wang C, Torpy JR, Bartonicek N, Wang T, Larsson L, Kaczorowski D, Weisenfeld NI, Uytingco CR, Chew JG, Bent ZW, Chan C-L, Gnanasambandapillai V, Dutertre C-A, Gluch L, Hui MN, Beith J, Parker A, Robbins E, Segara D, Cooper C, Mak C, Chan B, Warrier S, Ginhoux F, Millar E, Powell JE, Williams SR, Liu XS, O’Toole S, Lim E, Lundeberg J, Perou CM, Swarbrick A (2021) A single-cell and spatially resolved atlas of human breast cancers. Nat Genet 53(9):1334–1347
pubmed: 34493872
pmcid: 9044823
doi: 10.1038/s41588-021-00911-1
Jiang Y-Z, Ma D, Suo C, Shi J, Xue M, Hu X, Xiao Y, Yu K-D, Liu Y-R, Yu Y, Zheng Y, Li X, Zhang C, Hu P, Zhang J, Hua Q, Zhang J, Hou W, Ren L, Bao D, Li B, Yang J, Yao L, Zuo W-J, Zhao S, Gong Y, Ren Y-X, Zhao Y-X, Yang Y-S, Niu Z, Cao Z-G, Stover DG, Verschraegen C, Kaklamani V, Daemen A, Benson JR, Takabe K, Bai F, Li D-Q, Wang P, Shi L, Huang W, Shao Z-M (2019) Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies. Cancer Cell 35(3):428–440
pubmed: 30853353
doi: 10.1016/j.ccell.2019.02.001
Stuart T, Butler A, Hoffman P, Hafemeister C, Papalexi E, Mauck WM, Hao Y, Stoeckius M, Smibert P, Satija R (2019) Comprehensive integration of single-cell data. Cell 177(7):1888–1902
pubmed: 31178118
pmcid: 6687398
doi: 10.1016/j.cell.2019.05.031
Love MI, Huber W, Anders S (2014) Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15(12):550
pubmed: 25516281
pmcid: 4302049
doi: 10.1186/s13059-014-0550-8
Raouf A, Zhao Y, To K, Stingl J, Delaney A, Barbara M, Iscove N, Jones S, McKinney S, Emerman J, Aparicio S, Marra M, Eaves C (2008) Transcriptome analysis of the normal human mammary cell commitment and differentiation process. Cell Stem Cell 3(1):109–118
pubmed: 18593563
doi: 10.1016/j.stem.2008.05.018
Jin S, Guerrero-Juarez CF, Zhang L, Chang I, Ramos R, Kuan C-H, Myung P, Plikus MV, Nie Q (2021) Inference and analysis of cell-cell communication using Cell Chat. Nat Commun 12(1):1088
pubmed: 33597522
pmcid: 7889871
doi: 10.1038/s41467-021-21246-9
Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA (2018) Profiling Tumor infiltrating immune cells with CIBERSORT. Methods Mol Biol 1711:243–259
pubmed: 29344893
pmcid: 5895181
doi: 10.1007/978-1-4939-7493-1_12
Aran D, Hu Z, Butte AJ (2017) xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol 18(1):220
pubmed: 29141660
pmcid: 5688663
doi: 10.1186/s13059-017-1349-1
Yu G, Wang L-G, Han Y, He Q-Y (2012) clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 16(5):284–287
pubmed: 22455463
pmcid: 3339379
doi: 10.1089/omi.2011.0118
Yu G, He Q-Y (2016) ReactomePA: an R/Bioconductor package for reactome pathway analysis and visualization. Mol BioSyst 12(2):477–479
pubmed: 26661513
doi: 10.1039/C5MB00663E
Jézéquel P, Frénel J-S, Campion L, Guérin-Charbonnel C, Gouraud W, Ricolleau G, Campone M (2013) bc-GenExMiner 3.0: new mining module computes breast cancer gene expression correlation analyses. Database J Biol Databases Curation 2013:060
Lambert SA, Jolma A, Campitelli LF, Das PK, Yin Y, Albu M, Chen X, Taipale J, Hughes TR, Weirauch MT (2018) The human transcription factors. Cell 172(4):650–665
pubmed: 29425488
doi: 10.1016/j.cell.2018.01.029
Chin C-H, Chen S-H, Wu H-H, Ho C-W, Ko M-T, Lin C-Y (2014) cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst Biol 8 Suppl 4(Suppl 4):S11
pubmed: 25521941
doi: 10.1186/1752-0509-8-S4-S11
Becht E, Giraldo NA, Lacroix L, Buttard B, Elarouci N, Petitprez F, Selves J, Laurent-Puig P, Sautès-Fridman C, Fridman WH, de Reyniès A (2016) Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol 17(1):218
pubmed: 27765066
pmcid: 5073889
doi: 10.1186/s13059-016-1070-5
Bhattacharya S, Andorf S, Gomes L, Dunn P, Schaefer H, Pontius J, Berger P, Desborough V, Smith T, Campbell J, Thomson E, Monteiro R, Guimaraes P, Walters B, Wiser J, Butte AJ (2014) ImmPort: disseminating data to the public for the future of immunology. Immunol Res 58(2–3):234–239
pubmed: 24791905
doi: 10.1007/s12026-014-8516-1
Mabbott NA, Baillie JK, Brown H, Freeman TC, Hume DA (2013) An expression atlas of human primary cells: inference of gene function from coexpression networks. BMC Genomics 14:632
pubmed: 24053356
pmcid: 3849585
doi: 10.1186/1471-2164-14-632
Miao Y-R, Zhang Q, Lei Q, Luo M, Xie G-Y, Wang H, Guo A-Y (2020) ImmuCellAI: a unique method for comprehensive T-cell subsets abundance prediction and its application in cancer immunotherapy. Adv Sci 7(7):1902880
doi: 10.1002/advs.201902880
Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, Hoang CD, Diehn M, Alizadeh AA (2015) Robust enumeration of cell subsets from tissue expression profiles. Nat Methods 12(5):453–457
pubmed: 25822800
pmcid: 4739640
doi: 10.1038/nmeth.3337
Nirmal AJ, Regan T, Shih BB, Hume DA, Sims AH, Freeman TC (2018) Immune cell gene signatures for profiling the microenvironment of solid tumors. Cancer Immunol Res 6(11):1388–1400
pubmed: 30266715
doi: 10.1158/2326-6066.CIR-18-0342
Lehmann BD, Pietenpol JA, Tan AR (2015) Triple-negative breast cancer: molecular subtypes and new targets for therapy. American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting, pp e31–e39
Del Zotto G, Marcenaro E, Vacca P, Sivori S, Pende D, Della Chiesa M, Moretta F, Ingegnere T, Mingari MC, Moretta A, Moretta L (2017) Markers and function of human NK cells in normal and pathological conditions. Cytometry Part Clin Cytometry 92(2):100–114
doi: 10.1002/cyto.b.21508
Marcenaro E, Augugliaro R, Falco M, Castriconi R, Parolini S, Sivori S, Romeo E, Millo R, Moretta L, Bottino C, Moretta A (2003) CD59 is physically and functionally associated with natural cytotoxicity receptors and activates human NK cell-mediated cytotoxicity. Eur J Immunol 33(12):3367–3376
pubmed: 14635045
doi: 10.1002/eji.200324425
Sharma R, Das A (2018) IL-2 mediates NK cell proliferation but not hyperactivity. Immunol Res 66(1):151–157
pubmed: 29256180
doi: 10.1007/s12026-017-8982-3
Wang Z, Guan D, Huo J, Biswas SK, Huang Y, Yang Y, Xu S, Lam K-P (2021) IL-10 enhances human natural killer cell effector functions via metabolic reprogramming regulated by mTORC1 signaling. Front Immunol 12:619195
pubmed: 33708210
pmcid: 7940510
doi: 10.3389/fimmu.2021.619195
Robertson MJ (2002) Role of chemokines in the biology of natural killer cells. J Leukoc Biol 71(2):173–183
pubmed: 11818437
doi: 10.1189/jlb.71.2.173
Fulda S, Gorman AM, Hori O, Samali A (2010) Cellular stress responses: cell survival and cell death. Int J Cell Biol 2010:214074
pubmed: 20182529
pmcid: 2825543
doi: 10.1155/2010/214074
Tang F, Li J, Qi L, Liu D, Bo Y, Qin S, Miao Y, Yu K, Hou W, Li J, Peng J, Tian Z, Zhu L, Peng H, Wang D, Zhang Z (2023) A pan-cancer single-cell panorama of human natural killer cells. Cell 186(19):4235–4251
pubmed: 37607536
doi: 10.1016/j.cell.2023.07.034
Crozat K, Eidenschenk C, Jaeger BN, Krebs P, Guia S, Beutler B, Vivier E, Ugolini S (2011) Impact of β2 integrin deficiency on mouse natural killer cell development and function. Blood 117(10):2874–2882
pubmed: 21239699
doi: 10.1182/blood-2010-10-315457
Takheaw N, Earwong P, Laopajon W, Pata S, Kasinrerk W (2019) Interaction of CD99 and its ligand upregulates IL-6 and TNF-α upon T cell activation. PLoS ONE 14(5):e0217393
pubmed: 31120992
pmcid: 6532917
doi: 10.1371/journal.pone.0217393
Gebhardt C, Németh J, Angel P, Hess J (2006) S100A8 and S100A9 in inflammation and cancer. Biochem Pharmacol 72(11):1622–1631
pubmed: 16846592
doi: 10.1016/j.bcp.2006.05.017
Xu Z, Cheng C, Kong R, Liu Y, Wang S, Ma Y, Xing X (2021) S100A8 and S100A9, both transcriptionally regulated by PU.1, promote epithelial-mesenchymal transformation (EMT) and invasive growth of dermal keratinocytes during scar formation post burn. Aging 13(11):15523–15537
pubmed: 34099591
pmcid: 8221299
doi: 10.18632/aging.203112
Segovia-Mendoza M, Morales-Montor J (2019) Immune tumor microenvironment in breast cancer and the participation of estrogen and its receptors in cancer physiopathology. Front Immunol 10:348
pubmed: 30881360
pmcid: 6407672
doi: 10.3389/fimmu.2019.00348
Liu X, Lu Y, Huang J, Xing Y, Dai H, Zhu L, Li S, Feng J, Zhou B, Li J, Xia Q, Li J, Huang M, Gu Y, Su S (2022) CD16+ fibroblasts foster a trastuzumab-refractory microenvironment that is reversed by VAV2 inhibition. Cancer Cell 40(11):1341–1357
pubmed: 36379207
doi: 10.1016/j.ccell.2022.10.015
Sconocchia G, Zlobec I, Lugli A, Calabrese D, Iezzi G, Karamitopoulou E, Patsouris ES, Peros G, Horcic M, Tornillo L, Zuber M, Droeser R, Muraro MG, Mengus C, Oertli D, Ferrone S, Terracciano L, Spagnoli GC (2011) Tumor infiltration by FcγRIII (CD16)+ myeloid cells is associated with improved survival in patients with colorectal carcinoma. Int J Cancer 128(11):2663–2672
pubmed: 20715106
doi: 10.1002/ijc.25609
Li J, Shu X, Xu J, Su SM, Chan UI, Mo L, Liu J, Zhang X, Adhav R, Chen Q, Wang Y, An T, Zhang X, Lyu X, Li X, Lei JH, Miao K, Sun H, Xing F, Zhang A, Deng C, Xu X (2022) S100A9-CXCL12 activation in BRCA1-mutant breast cancer promotes an immunosuppressive microenvironment associated with resistance to immunotherapy. Nat Commun 13(1):1481
pubmed: 35304461
pmcid: 8933470
doi: 10.1038/s41467-022-29151-5
Debien V, De Caluwé A, Wang X, Piccart-Gebhart M, Tuohy VK, Romano E, Buisseret L (2023) Immunotherapy in breast cancer: an overview of current strategies and perspectives. NPJ Breast Cancer 9(1):7
pubmed: 36781869
pmcid: 9925769
doi: 10.1038/s41523-023-00508-3
Crespo J, Sun H, Welling TH, Tian Z, Zou W (2013) T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. Curr Opin Immunol 25(2):214–221
pubmed: 23298609
pmcid: 3636159
doi: 10.1016/j.coi.2012.12.003
Miller BC, Sen DR, Al Abosy R, Bi K, Virkud YV, LaFleur MW, Yates KB, Lako A, Felt K, Naik GS, Manos M, Gjini E, Kuchroo JR, Ishizuka JJ, Collier JL, Griffin GK, Maleri S, Comstock DE, Weiss SA, Brown FD, Panda A, Zimmer MD, Manguso RT, Hodi FS, Rodig SJ, Sharpe AH, Haining WN (2019) Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. Nat Immunol 20(3):326–336
pubmed: 30778252
pmcid: 6673650
doi: 10.1038/s41590-019-0312-6
Roe K (2022) NK-cell exhaustion, B-cell exhaustion and T-cell exhaustion-the differences and similarities. Immunology 166(2):155–168
pubmed: 35266556
doi: 10.1111/imm.13464
Judge SJ, Murphy WJ, Canter RJ (2020) Characterizing the dysfunctional NK cell: assessing the clinical relevance of exhaustion, anergy, and senescence. Front Cell Infect Microbiol 10:49
pubmed: 32117816
pmcid: 7031155
doi: 10.3389/fcimb.2020.00049
Montes CL, Chapoval AI, Nelson J, Orhue V, Zhang X, Schulze DH, Strome SE, Gastman BR (2008) Tumor-induced senescent T cells with suppressor function: a potential form of tumor immune evasion. Can Res 68(3):870–879
doi: 10.1158/0008-5472.CAN-07-2282
Chu Y, Dai E, Li Y, Han G, Pei G, Ingram DR, Thakkar K, Qin J-J, Dang M, Le X, Hu C, Deng Q, Sinjab A, Gupta P, Wang R, Hao D, Peng F, Yan X, Liu Y, Song S, Zhang S, Heymach JV, Reuben A, Elamin YY, Pizzi MP, Lu Y, Lazcano R, Hu J, Li M, Curran M, Futreal A, Maitra A, Jazaeri AA, Ajani JA, Swanton C, Cheng X-D, Abbas HA, Gillison M, Bhat K, Lazar AJ, Green M, Litchfield K, Kadara H, Yee C, Wang L (2023) Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance. Nat Med 29(6):1550–1562
pubmed: 37248301
doi: 10.1038/s41591-023-02371-y
Ascierto ML, Idowu MO, Zhao Y, Khalak H, Payne KK, Wang X-Y, Dumur CI, Bedognetti D, Tomei S, Ascierto PA, Shanker A, Bear HD, Wang E, Marincola FM, De Maria A, Manjili MH (2013) Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients. J Transl Med 11:145
pubmed: 23758773
pmcid: 3694475
doi: 10.1186/1479-5876-11-145
Stabile H, Fionda C, Gismondi A, Santoni A (2017) Role of distinct natural killer cell subsets in anticancer response. Front Immunol 8:293
pubmed: 28360915
pmcid: 5352654
doi: 10.3389/fimmu.2017.00293
Thacker G, Henry S, Nandi A, Debnath R, Singh S, Nayak A, Susnik B, Boone MM, Zhang Q, Kesmodel SB, Gumber S, Das GM, Kambayashi T, DosSantos CO, Chakrabarti R (2023) Immature natural killer cells promote progression of triple-negative breast cancer. Sci Transl Med 15(686): 1l4414
Bouzidi L, Triki H, Charfi S, Kridis WB, Derbel M, Ayadi L, Sellami-Boudawara T, Cherif B (2021) Prognostic value of natural killer cells besides tumor-infiltrating lymphocytes in breast cancer tissues. Clin Breast Cancer 21(6):e738–e747
pubmed: 33727019
doi: 10.1016/j.clbc.2021.02.003